Daily Endocrinology Research Analysis
Three impactful endocrinology studies stood out: a pediatric randomized trial showed that an app-guided progressive resistance training program safely reduced insulin requirements in type 1 diabetes. A mechanistic-clinical study linked compartment-specific metabolomic responses to insulin with future type 2 diabetes risk. A large retrospective analysis challenged the reliability of aldosterone suppression tests in primary aldosteronism, with implications for diagnostic pathways.
Summary
Three impactful endocrinology studies stood out: a pediatric randomized trial showed that an app-guided progressive resistance training program safely reduced insulin requirements in type 1 diabetes. A mechanistic-clinical study linked compartment-specific metabolomic responses to insulin with future type 2 diabetes risk. A large retrospective analysis challenged the reliability of aldosterone suppression tests in primary aldosteronism, with implications for diagnostic pathways.
Research Themes
- Digital therapeutics and exercise in diabetes
- Metabolomic signatures and precision risk prediction
- Diagnostic paradigm shifts in endocrine hypertension
Selected Articles
1. Effect of Diactive-1 mHealth-Supported Progressive Resistance Training on Insulin Requirements, Glycemic Stability, and Muscular Strength in Children and Adolescents With Type 1 Diabetes: A Parallel-Group Randomized Controlled Trial.
In a 24-week randomized trial of 62 youths with type 1 diabetes, an mHealth-guided progressive resistance training program reduced daily insulin dose by 0.17 units/kg versus usual care and improved multiple strength metrics without increasing hypoglycemia or glycemic risk. The intervention was feasible with low attrition.
Impact: Demonstrates a scalable, app-guided exercise intervention that safely reduces insulin requirements in pediatric type 1 diabetes while enhancing strength, addressing a key clinical need beyond pharmacotherapy.
Clinical Implications: Pediatric endocrinology teams can incorporate structured, app-guided resistance training alongside CGM into routine care to reduce insulin dosing while maintaining glycemic safety; protocols should include proactive insulin adjustment and strength progression monitoring.
Key Findings
- Daily insulin dose decreased within the intervention group and versus usual care (MD −0.17 units/kg, 95% CI −0.26 to −0.07).
- No increase in glycemic risk index or hypoglycemic events with the training program.
- Muscular strength improved: handgrip (MD 2.90 kg), 1RM (MD 1.34), and power (MD 0.97).
Methodological Strengths
- Randomized parallel-group design with intention-to-treat analyses using linear mixed models.
- Objective insulin and glycemic data from connected platforms (LibreView/CareLink) and standardized strength assessments.
Limitations
- Modest sample size from a single program limits generalizability.
- Short intervention duration; effects on HbA1c change were not detailed.
Future Directions: Larger multicenter RCTs with longer follow-up should evaluate sustained glycemic outcomes (HbA1c, time in range), dosing algorithms for insulin adjustment, and cost-effectiveness of app-based resistance training.
OBJECTIVE: To evaluate the effects of resistance training supported by the mobile health application Diactive-1 on the daily insulin dose and glycemic parameters in children and adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this 24-week randomized clinical trial, Diactive-1 generated progressive overload resistance training sessions tailored to real-time glycemia and provided educational support. Insulin and glycemic parameters were collected from LibreView or CareLink, whereas glycosylated hemoglobin (HbA1c) was extracted from medical records. Muscular strength was assessed using a handgrip dynamometer and e-GYM machines, targeting pushing, pulling, and lower-limb movements. The effect was analyzed using linear mixed models. RESULTS: Sixty-two participants (age: 8-18 years, girls: 48%) with type 1 diabetes (HbA1c: 7.6% [60.4 mmol/mol]) were allocated to the usual care (n = 32) or the Diactive-1 group (n = 30). Daily insulin dose reductions were observed within the Diactive-1 group (mean difference [MD] -0.10 units/kg, 95% CI -0.18 to -0.01) and when compared with usual care (MD -0.17 units/kg, 95% CI -0.26 to -0.07). No adverse effects were observed on the glycemic risk index or the incidence of hypoglycemic events. Finally, handgrip strength (MD 2.90 kg, 95% CI 1.57-4.22), one-repetition maximum strength (MD 1.34, 95% CI 0.21-2.46), and muscular power (MD 0.97, 95% CI 0.01-1.93) increased. Four participants (6.5%) withdrew from the study. CONCLUSIONS: Diactive-1 appears to be a safe and feasible adjunct to standard care in children and adolescents with type 1 diabetes. Its resistance training component effectively reduced insulin requirements and improved muscular strength, without increasing the risk of adverse glycemic events.
2. Compartment-Specific Metabolic Alterations to Insulin Reflect Adiposity-Driven Variation and Predict Type 2 Diabetes.
During hyperinsulinemic-euglycemic clamp, 79.5% of plasma and 15.8% of muscle metabolites changed, with adiposity amplifying lipid responses; individuals with T2D showed higher triglycerides and lower TCA intermediates. A metabolomic insulin response score predicted incident T2D in the Women's Health Initiative (HR 1.20 per SD).
Impact: Bridges mechanistic physiology with population risk by linking insulin-driven metabolomic signatures to future diabetes, enabling earlier identification beyond traditional risk factors.
Clinical Implications: Metabolomic response profiles to insulin may enhance T2D risk stratification and guide personalized prevention; translation will require standardized assays and validation across sexes, ancestries, and clinical settings.
Key Findings
- Hyperinsulinemia altered 79.5% of plasma and 15.8% of muscle metabolites, notably affecting fatty acids, lactate, and amino acids.
- Adiposity amplified insulin-induced increases in plasma lipids; T2D was linked to higher triglycerides and lower TCA intermediates during clamp.
- An insulin response metabolomic score predicted incident T2D in WHI (HR 1.20 per SD, 95% CI 1.09–1.32).
Methodological Strengths
- Paired plasma and muscle metabolomics during hyperinsulinemic-euglycemic clamp for compartment-specific insights.
- Prospective validation of a derived risk score in a large, long-term cohort (WHI).
Limitations
- Clamp sample size was modest (n=80) and WHI validation focused on women, limiting generalizability.
- Metabolomic platforms and analytical pipelines require standardization for clinical translation.
Future Directions: External validation across diverse populations and integration with genetic and clinical risk models; interventional studies testing whether modifying metabolomic signatures reduces T2D incidence.
CONTEXT: The metabolic mechanisms underlying insulin resistance (IR) are not fully understood. Metabolomic profiling can reveal compartment-specific variations and identify individuals at risk for type 2 diabetes (T2D). OBJECTIVE: To characterize insulin-induced metabolomic changes during a hyperinsulinemic-euglycemic clamp and evaluate a derived risk score's predictive value for T2D. DESIGN, SETTING, AND PARTICIPANTS: Clamp studies were conducted in 80 adults (38 with T2D, 42 without) to measure plasma and muscle metabolites in fasting and hyperinsulinemic states. An IR metabolomic score was developed and tested in a prospective case-control study (367 cases, 910 controls) from the Women's Health Initiative (28.5-year follow-up). MAIN OUTCOME MEASURES: Metabolite changes during hyperinsulinemia and incident T2D. RESULTS: Hyperinsulinemia altered 79.5% of plasma metabolites (notably fatty acids, lactate, pyruvate) and 15.8% of muscle metabolites (e.g., branched-chain and aromatic amino acids). T2D was associated with higher triglycerides and lower tricarboxylic acid intermediates during clamp. Adiposity amplified insulin-induced increases in plasma lipids. The risk score predicted incident T2D (HR 1.20 per SD; 95% CI: 1.09-1.32; P = 7.4 × 10⁻⁴). CONCLUSIONS: Compartment-specific metabolic responses to insulin are shaped by adiposity and predict future T2D risk, supporting use of metabolomic signatures for early identification and prevention.
3. Discordance and shortcomings of aldosterone suppression tests in primary aldosteronism.
In 531 high-probability primary aldosteronism patients undergoing both SST and CCT, diagnostic yields varied widely by criteria, inter-test discordance was frequent (10.9–51.6%), and false negatives occurred even in surgically cured, lateralizing disease. These suppression tests did not reliably predict lateralization.
Impact: Challenges current diagnostic pathways by demonstrating substantial inconsistency and limited predictive value of widely used suppression tests, potentially reshaping confirmation and subtyping strategies in primary aldosteronism.
Clinical Implications: For high-risk PA, clinicians should be cautious in relying on SST/CCT to confirm disease or predict unilateral involvement; earlier adrenal vein sampling and integrated clinical-imaging decision-making may reduce misclassification.
Key Findings
- Diagnostic rates ranged from 47.8% to 97.2% depending on SST/CCT cutoffs, indicating poor robustness.
- Inter-test discordance between SST and CCT was high (10.9%–51.6%).
- Even among lateralizing PA and surgically cured patients, a substantial fraction had negative or false-negative SST/CCT results.
Methodological Strengths
- Large single-center cohort with both suppression tests performed in the same patients.
- Linked test results to lateralization and surgical biochemical outcomes.
Limitations
- Retrospective design with potential selection bias and center-specific protocols.
- Heterogeneity in diagnostic thresholds may influence discordance rates.
Future Directions: Prospective, standardized comparisons of suppression tests versus direct adrenal vein sampling; development of more accurate biochemical or imaging markers for PA confirmation and lateralization.
BACKGROUND: The saline suppression test (SST) and the captopril challenge test (CCT) have traditionally been used to confirm or exclude primary aldosteronism (PA). New guidelines recommend using these tests to predict the likelihood of unilateral PA. This study evaluated the diagnostic accuracy, consistency, and clinical implications of these tests. METHODS: We conducted a retrospective study of 531 patients with high-probability features of PA who underwent both SST and CCT to evaluate their accuracy and ability to predict unilateral PA. Adrenal lateralization and surgical treatment decisions were guided by individualized clinical judgment rather than strictly relying on SST/CCT results. RESULTS: The rate of PA diagnosis ranged from 47.8% to 97.2% based on SST and CCT criteria. Discordance rates between SST and CCT ranged from 10.9% to 51.6%. In analyses restricted to only patients with clinically overt PA, where suppression testing is not considered necessary, the positivity rates of the SST and CCT were still suboptimal and test discordance persisted. Among patients with lateralizing PA, 6.6% to 27.9% had either a negative SST or CCT interpretation, and among those who achieved Primary Aldosteronism Surgical Outcome-defined biochemical cure after unilateral adrenalectomy, 4.1% to 39.8% had either a negative SST or CCT, and up to 5.1% had false-negative results on both tests. CONCLUSIONS: Well-established aldosterone suppression tests for PA demonstrated substantial inconsistency, false-negative interpretations, and the inability to reliably predict lateralization outcomes in PA. Aldosterone suppression testing, using SST and CCT, lack accuracy for the diagnosis and subtyping of PA in high-risk patients.